There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Flt-3


Flt-3 Molecule Information

Name:Tyrosine-protein kinase receptor FLT3
Target Synonym:STK-1;Fetal liver kinase-2;FLT-3;STK1;Fms-like tyrosine kinase 3;FLT3;FL cytokine receptor;FLK-2;FLK2;Receptor-type tyrosine-protein kinase FLT3;Stem cell tyrosine kinase 1;CD135 ;CD_antigen=CD135
Number of Launched Drugs:10
Number of Drugs in Clinical Trials:57
Lastest Research Phase:Approved

Flt-3 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
FL3-M52H6 Mouse Mouse Flt-3 / Flk-2 Protein, His Tag
FL3-H5258 Human Human Flt-3 / Flk-2 Protein, Fc Tag

Flt-3 Part of Bioactivity data

Human Flt-3, Fc TagHuman Flt-3, Fc Tag (Cat. No. FL3-H5258) ELISA bioactivity

Immobilized Human Flt-3 Ligand, Tag Free (Cat. No. FLL-H5218) at 1 μg/mL (100 μL/well) can bind Human Flt-3, Fc Tag (Cat. No. FL3-H5258) with a linear range of 2-31 ng/mL (QC tested).

Flt-3 Molecule Synonym Name


Flt-3 Molecule Background

Flt-3(Receptor-type tyrosine-protein kinase FLT3) is also known as FLK-2(Fetal liver kinase-2), STK-1(Stem cell tyrosine kinase 1), CD135. FLT3 is a cytokine receptor which belongs to the receptor tyrosine kinase class III. Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.

Flt-3 References

Flt-3 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Quizartinib AC-010220; AC-220; ASP-2689 Approved Ambit biosciences, Daiichi Sankyo, Astellas Quizartinib Hydrochloride 日本 Acute myeloid Leukemia (AML) 第一三共 2019-06-18 00:00:00.0 Acute myeloid Leukemia (AML) Details
Brigatinib AP-26113 Approved Ariad, Takeda ALUNBRIG fda Anaplastic lymphoma kinase (ALK)-positive NSCLC, Metastatic non-small cell lung cancer ARIAD 2017-04-28 Anaplastic lymphoma kinase (ALK)-positive NSCLC, Metastatic non-small cell lung cancer Details
Gilteritinib fumarate ASP-2215; ASP-2215 hemifumarate; 66D-92MGC8M (UNII code) Approved Astellas Gilteritinib fumarate 日本 Acute myeloid Leukemia (AML) 安斯泰来 2018-09-21 00:00:00.0 Acute myeloid Leukemia (AML) Details
Sorafenib Tosylate BAY-54-9085; BAY-43-9006; BAY-43-0006; NSC-724772,BAY 43-9006,BAY54-9085,BAY43-9006,BAY 54-9085 Approved Onyx Pharmaceutical, Bayer NEXAVAR fda Differentiated thyroid cancer, Advanced renal cell carcinoma (RCC), Unresectable hepatocellular carcinoma BAYER HLTHCARE 2005-12-01 Differentiated thyroid cancer, Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Unresectable hepatocellular carcinoma, Hepatocellular carcinoma (HCC) Details
Pexidartinib PLX-3397 Approved Daiichi Sankyo TURALIO fda Tenosynovial giant cell tumor (TGCT) DAIICHI SANKYO INC 2019-08-02 Tenosynovial giant cell tumor (TGCT) Details
Fedratinib SAR-302503; TG-101348 Approved Sanofi, Celgene, Impact Biomedicines INREBIC fda Myelofibrosis IMPACT 2019-08-16 Myelofibrosis Details
Sunitinib Malate PNU-290940; SU-11248; SU-010398; SU-011248-L-malate salt; PHA-290940; PHA-290940AD; PNU-290940AD; GB-102,SU11248,PNU 290940,PNU290940,SU 11248 Approved Pfizer SUTENT fda Renal cell carcinoma, Gastrointestinal stromal tumors (GISTs), Advanced renal cell carcinoma (RCC), Pancreatic neuroendocrine tumors (pNET) CPPI CV 2006-01-26 Renal cell carcinoma, Gastrointestinal stromal tumors (GISTs), Advanced renal cell carcinoma (RCC), Pancreatic neuroendocrine tumors (pNET), Renal carcinoma Details
Ponatinib Hydrochloride AP-24534; AP24534 HCl; AP24534 hydrochloride; AP24534-HCL; INCB-84344,AP 24534,AP24534 Approved Ariad ICLUSIG fda Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML ) ARIAD 2012-12-14 Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML ) Details
Midostaurin PKC-412; CGP-41231; CGP-41251; PKC-412A Approved Novartis RYDAPT fda Systemic mastocytosis with associated hematological neoplasm, Aggressive systemic mastocytosis (ASM), Acute myeloid Leukemia (AML), Mast cell leukemia NOVARTIS 2017-04-28 Systemic mastocytosis with associated hematological neoplasm, Aggressive systemic mastocytosis (ASM), Acute myeloid Leukemia (AML), Mast cell leukemia Details
Nintedanib Esylate BIBF-1120,BIBF 1120,BIBF1120 Approved Boehringer Ingelheim OFEV fda Idiopathic pulmonary fibrosis (IPF) BOEHRINGER INGELHEIM 2014-10-15 Interstitial lung disease, Non small cell lung cancer (NSCLC), Idiopathic pulmonary fibrosis (IPF) Details

Flt-3 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
FN-1501 FN-1501 Phase Ⅰ China Pharmaceutical University, Fosun Pharma Leukemia Details
LY-2457546 LY-2457546 Phase Ⅰ Lilly Acute myeloid Leukemia (AML) Details
Tozasertib VX-680; MK-0457,VX680,MK0457 Phase Ⅱ Vertex, Merck Sharp & Dohme Solid tumours, Leukemia Details
Crenolanib Besylate ARO-002; ARO-002-26; CP-868596; CP-868596-26; IND-112201 Phase Ⅲ Pfizer, AROG Pharmaceuticals Gastrointestinal stromal tumors (GISTs), Acute myeloid Leukemia (AML) Details
L-21649 L-21649; L-000021649 Phase Ⅰ Merck Sharp & Dohme Solid tumours, Acute myeloid Leukemia (AML) Details
Flysyn 4G8-SDIEM,4G8 SDIEM,4G8SDIEM Phase Ⅱ Synimmune Acute myeloid Leukemia (AML) Details
CTx-0294886 AMP-886; CTx-294886 Preclinical Cancer Therapeutics, Amplia Therapeutics Limited, Cancer Research Technology Pulmonary fibrosis, Cancer Details
JNJ-28312141 JNJ-28312141,JNJ28312141,JNJ 28312141 Phase Ⅰ Johnson & Johnson Solid tumours, Rheumatoid arthritis (RA) Details
AM-5992 AM-5992 Preclinical Amgen Acute myeloid Leukemia (AML) Details
E-6201 E-6201,E6201 Phase Ⅱ Eisai, QuintilesIMS, Strategia Therapeutics, Spirita Oncology Myelodysplastic syndrome (MDS), Chronic myelomonocytic leukemia(CMML), Acute lymphoblastic leukaemia (ALL) Details
XY0206 XY-0206 Phase Ⅰ Shijiazhuang Yiling Pharmaceutical, Nanjing University of Chinese Medicine Acute myeloid Leukemia (AML) Details
SKLB-1028 SKLB-1028 Phase Ⅱ China Shijiazhuang Pharmaceutical Group/CSPC, Sichuan University Acute myeloid Leukemia (AML) Details
Amuvatinib MP-470; HPK-56,MP470,HPK56 Phase Ⅱ Astex Pharmaceuticals Small cell lung cancer (SCLC) Details
AMG-427 (Amgen) AMG-427 Phase Ⅰ Amgen Acute myeloid Leukemia (AML) Details
Silvestrol Preclinical Ohio State University, National Cancer Institute Cancer Details
SU-014813 SU-014813; SU-14813 Phase Ⅱ Pfizer Breast cancer Details
FF-10101 FF-10101-01; FF-10101; FF-10101 succinate Phase Ⅱ FUJIFILM Corporation, Nagoya University Acute myeloid Leukemia (AML) Details
KW-2449 KW-2449,KW2449 Phase Ⅱ Kyowa Hakko Kirin Acute myeloid Leukemia (AML), Hematological cancer Details
MRX-2843 UNC-2025; MRX-2843; UNC-2371 Phase Ⅰ University of North Carolina, Meryx, University of Colorado at Denver, Betta Solid tumours Details
Tandutinib MLN-0518; MLN-518; CT-53518,MLN0518,MLN518,CT53518 Phase Ⅱ Takeda Renal cell carcinoma, Acute myeloid Leukemia (AML) Details
SKI-G-801 SKI-G-801; G-801; G-749 Hydrochloride Phase Ⅰ Oscotec Acute myeloid Leukemia (AML) Details
FLX-925 FLX-925; AMG-925,FLX925,AMG925 Phase Ⅰ Amgen, RAPT Therapeutics Acute myeloid Leukemia (AML) Details
Ningetinib Tosylate CT-053-PTSA; CT-053 Phase Ⅱ HEC Pharm Non small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC), Renal carcinoma Details
Pacritinib ONX-0803; SB-1518,ONX0803,SB1518 Phase Ⅲ Concert, S*BIO, CTI BioPharma, Baxter Myelofibrosis, Acute myeloid Leukemia (AML) Details
QBH-196 QBH-196 Phase Ⅰ Shenyang Pharmaceutical University Gastric cancer Details
HYML-122 CHMFL-FLT3-122; HYML-122 Phase Ⅰ Hefei Cosource Pharmaceuticals, Hefei Institute of Physical Science, Chinese Academy of Sciences Acute myeloid Leukemia (AML) Details
Dovitinib CHIR-258; GFKI-258; CHIR-258LC; TKI-258; NVP-TKI258,GFKI258,CHIR258,TKI258 Phase Ⅲ Novartis Renal cell carcinoma, Solid tumours Details
SGI-1776 SGI-1776; SG-0407,SGI1776,SG0407 Phase Ⅰ Astex Pharmaceuticals Prostate cancer, Non-Hodgkin's lymphoma (NHL) Details
QLNC-3A6 Di-Maleate Phase Ⅰ Qilu Pharmaceutical, Qilu Antibiotics (Linyi) Pharmaceutical Solid tumours Details
AT-9283 AT-9283,AT9283 Phase Ⅱ Otsuka Multiple myeloma (MM) Details
AKN-028 AKN-028; BVT-II; BVT-63628 Phase Ⅱ Akinion Acute myeloid Leukemia (AML) Details
LOXO-102 LOXO-102; LOXO-103; LOXO-104 Preclinical Array BioPharma, Lilly Cancer Details
IMC EB10 Phase Ⅰ Lilly Acute granulocytic leukemia Details
Fms-like tyrosine kinase 3 ligand (Celldex Therapeutics) CDX-301 Phase Ⅱ Amgen, Celldex, National Cancer Institute Non small cell lung cancer (NSCLC) Details
CG-806 CG-026806; CG-806 Phase Ⅱ CrystalGenomics, Aptose Acute myeloid Leukemia (AML) Details
Lestaurtinib A-154475.0; CEP-701; KT-5555; SP-924; SPM-924 Phase Ⅲ Kyowa Hakko Kirin, Cephalon Acute lymphoblastic leukaemia (ALL) Details
AMG-553 AMG-553,AMG 553,AMG553 Phase Ⅰ Amgen Acute myeloid Leukemia (AML) Details
Hydroxychloroquine/Sorafenib Phase Ⅰ VG Life Sciences Solid tumours, Ovarian cancer Details
HM-43239 Phase Ⅱ Hanmi Acute myeloid Leukemia (AML) Details
SC-71710 SC-71710; 4SC-203 Phase Ⅰ 4SC AG, ProQinase Acute myeloid Leukemia (AML) Details
XL-999 XL-999; EXEL-0999 Phase Ⅱ Exelixis, GlaxoSmithKline, Symphony Evolution Non small cell lung cancer (NSCLC), Renal cell carcinoma, Colorectal cancer, Multiple myeloma (MM), Acute myeloid Leukemia (AML), Ovarian cancer Details
Sorafenib/MG-005 MGD-1509 Phase Ⅱ Metagone Biotech, The General Hospital of the Three Armies Solid tumours Details
PLX-7486 PLX-7486; PLX7486-TsOH Phase Ⅱ Daiichi Sankyo Solid tumours, Pancreatic cancer Details
Clifutinib Besylate Phase Ⅰ HEC Pharm Acute myeloid Leukemia (AML) Details
DBPR-114 Phase Ⅰ National Health Research Institutes Cancer Details
AC-886 AC-886 Phase Ⅰ Daiichi Sankyo Acute myeloid Leukemia (AML) Details
MAX-40279 MAX-40279-001; MAX-40279-01; Max-1; Max-40279 Phase Ⅰ Maxinovel Pharmaceuticals Acute myeloid Leukemia (AML) Details
NMS-03592088 NMS-03592088; NMS-P088 Phase Ⅱ Nerviano Medical Sciences Acute myeloid Leukemia (AML), Chronic myeloid leukemia (CML ) Details
Mivavotinib TAK-659 Phase Ⅱ Takeda Diffuse large B cell lymphoma Details
Imidacrine C-1311; NSC-645809; XF-02; XLS-002 Phase Ⅱ University of Bradford, BTG plc, Antisoma Breast cancer, Colorectal cancer Details
CT-1578 SB-1578; CT-1578; ONX-0805,SB1578,CT1578,ONX0805 Phase Ⅰ S*BIO, CTI BioPharma, Onyx Pharmaceutical Rheumatoid arthritis (RA) Details
AG-2034 AG-2034; AGL-2034 Phase Ⅰ Yissum Solid tumours Details
SEL-24 MEN-1703;SEL-24;SEL-24 program;SEL-24-1;SEL-24-B489 Phase Ⅱ Selvita, Menarini Acute myeloid Leukemia (AML) Details
Zotiraciclib SB-1317; TG-02 Phase Ⅱ S*BIO, Tragara, Lee's Pharm, Zhaoke Oncology Glioblastoma, Anaplastic astrocytoma Details

This web search service is supported by Google Inc.